Atyr Pharma Inc [ATYR] stock is trading at $3.74, up 3.03%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on October 04, 2024, and set its price target to $17. On September 05, 2024, Jefferies initiated with a Buy rating and assigned a price target of $9 on the stock. Oppenheimer downgraded its rating to a Perform. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $22 as its price target on October 12, 2021. Piper Sandler started tracking with a Overweight rating for this stock on September 21, 2021, and assigned it a price target of $19. In a note dated May 10, 2021, Laidlaw initiated an Buy rating and provided a target price of $18 on this stock.
Atyr Pharma Inc [ATYR] stock has fluctuated between $1.42 and $4.22 over the past year. Atyr Pharma Inc [NASDAQ: ATYR] shares were valued at $3.74 at the most recent close of the market.
Analyzing the ATYR fundamentals
Atyr Pharma Inc [NASDAQ:ATYR] reported sales of 0.23M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -5.64% with Operating Profit Margin at -289.59%, Pretax Profit Margin comes in at -271.55%, and Net Profit Margin reading is -271.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.79 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.64 points at the first support level, and at 3.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.84, and for the 2nd resistance point, it is at 3.93.
Ratios To Look Out For
For context, Atyr Pharma Inc’s Current Ratio is 5.41. Also, the Quick Ratio is 5.41, while the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 1364.97, the price to book ratio is 4.34.
Transactions by insiders
Recent insider trading involved SCHIMMEL PAUL, Director, that happened on Jul 24 ’24 when 52300.0 shares were purchased. Director, SCHIMMEL PAUL completed a deal on Jul 22 ’24 to buy 41052.0 shares. Meanwhile, Director SCHIMMEL PAUL bought 6648.0 shares on Jul 23 ’24.
